Zelgen to present promising oncology data for ZG006 and ZG005 at CSCO 2025

Suzhou Zelgen Biopharmaceuticals will present clinical data and updates for Alveltamig (ZG006) and Nilvanstomig (ZG005) at the 28th Chinese Society of Clinical Oncology (CSCO) academic conference from September 10-14, 2025. ZG006, a tri-specific antibody, showed strong anti-tumor activity in initial studies. In the ZG006-002 study for relapsed/refractory SCLC, 10 mg Q2W (30 patients) and 30 mg Q2W (30 patients) achieved ORRs of 60.0% and 63.3%, with confirmed ORRs of 53.3%.

For ZG005, a recombinant humanized anti-PD-1/TIGIT bispecific antibody, phase I/II data for its combination with etoposide and cisplatin (EP) in first-line advanced neuroendocrine carcinoma patients will be presented. Among 60 evaluable patients, ZG005 20 mg/kg + EP therapy achieved an ORR of 63% (17/27), compared to 29.4% (5/17) for placebo + EP.

The company emphasizes that while these presentations highlight progress, the long and complex nature of drug development means these events will not significantly impact recent financial performance, and investors should remain cautious due to inherent risks.